Press Releases Archives | Page 12 of 116

Cellino’s iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation

July 1, 2025 By BioInformant Team Leave a Comment

AMT Designation Positions Cellino to Accelerate the Development of Scalable, Personalized Regenerative Medicines

CAMBRIDGE, Mass. — Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA’s Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER). This prestigious designation highlights the transformative potential of Cellino’s automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies. [Read more…]

STEMCELL Technologies Launches STEMprep™ System to Streamline Tissue Dissociation in Research

July 1, 2025 By BioInformant Team Leave a Comment

New instrument automates tissue processing for researchers in cancer, immunology and other science fields

VANCOUVER, British Columbia, June 27, 2025 –– To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. [Read more…]

Applied StemCell Launches hiEX™ Research iPSC Exosomes to Power Next-Generation Regenerative Medicine Research

June 25, 2025 By BioInformant Team Leave a Comment

MILPITAS, Calif., June 24, 2025 — Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration. [Read more…]

Winner of the “Biotherapies and Bioproduction” Call for Projects Under the France 2030 plan, EVerZom Receives €3M in Government Funding to Industrialize its Exosome Bioproduction Technology

June 20, 2025 By BioInformant Team Leave a Comment

Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the “Biotherapies and Bioproduction of Innovative Therapies” call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates. [Read more…]

L2 Bio Seeks Principal Investigators for FDA-Approved Phase 2B Clinical Trial of Adipose-Derived Stem Cell Treatment for Crohn’s Disease

June 19, 2025 By BioInformant Team Leave a Comment

HENDERSON, NV – June 12, 2025, www.L2Bio.com – L2 Bio, is the clear leader in adipose-derived stem cell banking. L2 Bio is the only AD-Stem Cell Banking company with an FDA Approved Investigational New Drug. L2 is actively recruiting qualified Principal Investigators for its recently FDA-approved Phase 2B clinical trial. This groundbreaking study will investigate a novel intravenous (IV) delivery of adipose-derived stem cells (ADSCs or ASCs) for the treatment of Crohn’s Disease utilizing autologous or first-degree blood relative sourced Adipose Derived Mesenchymal Stem Cells (AD-MSCs). A simple, virtually painless, 15-minute procedure from the subject or donor is likely to produce enough stem cells to treat the subject for the duration of the trial and likely the remainder of their life if necessary. [Read more…]